CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the “Company”), a biotechnology and precision fermentation company focused on using cellular agriculture to produce...

CB Therapeutics rapidly expands cellular agriculture capabilities at new facility CARLSBAD, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the “Company”), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human...

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board. Dr. Wright...

CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase...